REGN475

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

OsteoarthritisOsteoarthritis of the KneeOsteoarthritis, HipOsteoarthritis, KneeSciatica

Phase 1

A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee

CompletedNCT00944892

Regeneron PharmaceuticalsOsteoarthritis of the Knee

Start: 2009-08-31End: 2010-05-31Updated: 2011-12-08

Phase 2

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

CompletedNCT00991172

Regeneron PharmaceuticalsSciatica

Start: 2009-11-30End: 2010-05-31Updated: 2011-12-08

A Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Osteoarthritis of the Knee

WithdrawnNCT01239017

Regeneron PharmaceuticalsOsteoarthritis

Updated: 2015-03-18

Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip

CompletedNCT02447276

Regeneron PharmaceuticalsOsteoarthritis, Hip, Osteoarthritis, Knee

Start: 2015-05-31End: 2016-11-30Updated: 2017-03-27

Related Papers

The Effects of Fasinumab on Peripheral Nerve Function and Ganglion Anatomy: Results From a Randomized, Double-Blind, Placebo-Controlled Study in Patients With Pain Due to Osteoarthritis of the Knee or Hip, and a Series of Nonclinical Studies.

2025-10-24

Antibodies to watch in 2020.

2020-01-01328 citations